Trial Profile

A phase IIa clinical trial of REG-101 (MEDI5884) in Peripheral Artery Disease (PAD)

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 09 Feb 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

09 Feb 2022 New trial record
03 Feb 2022 According to a Regio Biosciences media release, the company has entered into an exclusive license agreement with AstraZeneca to further develop REG-101 (MEDI 5884). Under the terms of the agreement, AstraZeneca will provide an exclusive license to Regio for further development of REG-101, to address patients with high unmet medical needs, including PAD and cardiovascular disease. Regio will be solely responsible for all research, development, and commercial activities of REG-101.
03 Feb 2022 According to a Regio Biosciences media release, the company expects to initiate this trial in the second half of 2022. The company has partnered with CPC Clinical Research (CPC) and multiple clinical sites in the US to conduct a Phase 2a clinical trial in patients with peripheral artery disease.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com